Biosimilars Approval to Biogenerics in Clinical Practice

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a biosimilars. According to current literature, the following points on biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in biosimilars.

  • Biotechnologic drug
  • Monoclonal antibody
  • Fusion protein
  • Biologic drug
  • Anti–tumor necrosis factor

Related Conference of Biosimilars Approval to Biogenerics in Clinical Practice

November 11-12, 2019

20th Annual Pharma Middle East Congress

Renaissance Polat Istanbul Hotel | Istanbul, Turkey
December 02, 03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 25-26, 2020

23rd Asia Pacific Pharma Congress

| Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
May 27- 28, 2020

14 th World Drug Delivery Summit

| London, UK
June 15-16, 2020

cancer-research-2020

Barcelona, Spain
June 18-19 | 2020

6th World Congress on Medicinal Plants and Marine Drugs

Amsterdam, Netherlands
June 24-25, 2020

25th International Congress on Pharmaceutical Biotechnology

Amsterdam | Netherlands
June 29-30, 2020

12th World Congress on Neuropharmacology

Athens, Greece
August 17-18, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
August 26-27, 2020

33rdWorld Congress on Pharmacology

Barcelona, Spain
September 07-08, 2020

Global Summit on Generic Drugs and Quality Control

| Prague, Czech Republic
September 10-11, 2020

World Congress on Rare Diseases & Orphan Drugs

| Prague, Czech Republic
September 21-22, 2020

35th World Pharmacology and Toxicology Forum

Tokyo, Japan
November 09-10, 2020

2nd World Congress on Drug Discovery and Drug Design

| Tokyo, Japan
November 09-10, 2020

Annual Meet on Pharmacovigilance & Drug Safety

Tokyo, Japan
November 09-10 , 2020

Asia Pacific Pharmaceutics & Drug Delivery Congress

| Tokyo , Japan
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Biosimilars Approval to Biogenerics in Clinical Practice Conference Speakers

Recommended Sessions

Related Journals

Are you interested in